

Interoffice correspondence



Landsbergerstrasse 6-8
8000 Munich 2, FRG Germany
Phone: (089) 539376
Telex 324133 TRAVENOL

Mailing address:
P.O. Box 202429, 80001 Munich 2
Cable Code: Travenol Muenchen

*Hepatitis Serum
AHF*
Behringer - München

to: W. Termeer/Costa Mesa
from: P. Taub
subject: Behring AHF

date: February 2, 1979

cc: R. DeVreker; W. Thomas;
K. Harder; J. Crone-Edermann;
C. Schmergel; W. Thrasher;
C. Harding;

RECEIVED

FEB 15 1979

OFFICE OF
W. R. THOMAS, PH.D.

Following information obtained on Behring "hepatitis-safe, fibrinogen-free AHF":

Cryo first stabilized with buffer (amino-acid), then heated up to 55 °C during 6 to 7 minutes; Heating is done through jet stream allowing only small volume to be heated at one time. At this stage, the fibrinogen becomes fibrin, which is then filtered out. The fibrinogen-free cryo still containing Factor VIII, Albumin and cold insoluble Beta globulin (plus other proteins in minor concentrations) is further purified with glycine.)

After lyophilization, the product is pasteurized during 18 - 20 hours using the same procedure Behring first experimented with the now commercially available I.V. Plasminogen. The AHF concentrate is thus claimed to be hepatitis-safe. It has been tried in animals (chimpanzees or green monkeys?) and is now being tried clinically in a few centres in Germany.

In addition, Behring also claims a much stricter donor selection. They also redeployed the personnel working in the fractionation plant: all hepatitis antigen positive personnel have been removed and replaced by antibody (IgM, A and B) positive personnel.

PLAINTIFF

EXHIBIT NO 14

WORLDWIDE COURT
REPORTERS, INC.

MDL BAX007302
CONFIDENTIAL

Could you please urgently investigate the feasibility of pasteurization after lyophilization. I have just finished a tour of all the major centers in Germany and will summarize the latest developments in a separate memo. It is clear that with the number of competitors now on the market (8 companies + DRK) and the stagnant A/F consumption, a product innovation would be very timely to maintain our current price level and increase our market share.

With kind regards,

GRO-C

D. Taub

MDL BANOTUS
CONFIDENTIAL